Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | MELK | Q14680 | 1/20 | 0.30 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4732299 | 0.89 | CNR1 (0.31) | BDKRB1CNR1 | |
| SCHEMBL4734027 | 0.87 | KIF11 (0.39) | BDKRB1CNR1MELK | |
| SCHEMBL4731672 | 0.87 | NPC1 (0.33) | MAPTBDKRB1CNR1 | |
| SCHEMBL4730292 | 0.87 | BDKRB1 (0.35) | BDKRB1CNR1MELK | |
| SCHEMBL4728846 | 0.87 | TACR1 (0.36) | BDKRB1CNR1 | |
| SCHEMBL4731467 | 0.86 | TRPA1 (0.36) | BDKRB1CNR1 | |
| SCHEMBL4734018 | 0.85 | PDK2 (0.37) | SMN1; SMN2BDKRB1CNR1FASN | |
| SCHEMBL4735928 | 0.85 | BDKRB1 (0.35) | BDKRB1CNR1 | |
| SCHEMBL4735935 | 0.84 | MTNR1B (0.38) | BDKRB1CNR1 | |
| SCHEMBL4733336 | 0.84 | MCHR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273747-B2 | tert-Butyl (4-((4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino)-cyclohexyl)-methyl-carbamate; hedgehog pathway agonists; alopecia; angiogenesis; wound healing; alzheimer's disease; inhibit aging effects on skin | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20080193423-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194637-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080182859-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | CURIS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008057469-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | WYETH (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057468-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057497-A2 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193423-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | MAPT 4623/4885LIPG 3074/4885SMN1; SMN2 3725/4885 |
| US-20080194637-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | MAPT 4623/4885LIPG 3074/4885SMN1; SMN2 3725/4885 |
| US-20080182859-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | SHH, GLI1, SMO | MAPT 398/4885LIPG 2332/4885SMN1; SMN2 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.